A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.
A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.
isPeerReviewed
abstract
The genetic variant rs72824905 ...... PLCγ2 pathway as drug-target.
@en
authorList
type
label
A nonsynonymous mutation in PL ...... s the likelihood of longevity.
category
electronicVersions
journalAssociation
language
managingOrganisationalUnit
openAccessPermission
publicationStatuses
visibility
Publiek - Geen beperking
@nl
workflow
Validated
@en
author
datePublished
2019-05-27